Blog
RSS FeedPosted by Michael Wonder on 10 Sep 2021
ICER publishes evidence report on treatments for myasthenia gravis
10 September 2021 - While eculizumab and efgartigimod each provide important health benefits, both would need to be priced more than ...
Posted by Michael Wonder on 09 Sep 2021
Controversy over using quality adjusted life years in cost effectiveness analyses: a systematic literature review
8 September 2021 - Researchers and policy makers in the US are exploring the implementation of health technology assessment and value ...
Posted by Michael Wonder on 26 Aug 2021
ICER to assess treatments for COVID-19
26 August 2021 - Report will be subject of Midwest CEPAC meeting in April 2022; Draft Scoping Document open to public ...
Posted by Michael Wonder on 25 Aug 2021
ICER to assess novel agents to prevent chemotherapy-induced neutropenia
25 August 2021 - Report will be subject of CTAF meeting in April 2022; draft scoping document open to public comment ...
Posted by Michael Wonder on 24 Aug 2021
ICER uses observational real world evidence to update 2018 assessment on therapies for hereditary angioedema, finds therapies far less cost effective than earlier estimates
24 August 2021 - Patients initiating therapy in real world dataset had less frequent baseline attack rates than rates from clinical ...
Posted by Michael Wonder on 18 Aug 2021
ICER releases draft evidence report on mavacamten for hypertrophic cardiomyopathy
18 August 2021 - Public comment period now open until 15 September 2021; requests to make oral comment during public meeting ...
Posted by Michael Wonder on 17 Aug 2021
ICER publishes final evidence report and policy recommendations on therapies for atopic dermatitis
17 August 2021 - Given uncertainty about safety data on oral JAK inhibitors for other indications, a narrow majority of the ...
Posted by Michael Wonder on 05 Aug 2021
ICER publishes final evidence report and policy recommendations on aducanumab for Alzheimer’s disease
5 August 2021 - Independent appraisal committee unanimously determined the evidence is not adequate to demonstrate that aducanumab provides a net ...
Posted by Michael Wonder on 17 Jul 2021
Aduhelm pros and cons debated at ICER meeting
16 July 2021 - Biogen officials defended the company's Alzheimer's drug and criticised ICER's cost effectiveness report today at a meeting ...
Posted by Michael Wonder on 09 Jul 2021
ICER publishes evidence report on therapies for atopic dermatitis
9 July 2021 - Evidence demonstrates the JAK inhibitors abrocitinib and upadacitinib are effective treatments for atopic dermatitis, but safety concerns ...
Posted by Michael Wonder on 04 Jul 2021
ICER to test principle of fair access to fairly priced pharmaceuticals
2 July 2021 - The controversial approval last month by the FDA of Aduhelm (aducanumab) for patients with early-stage Alzheimer’s disease ...
Posted by Michael Wonder on 30 Jun 2021
ICER to assess treatment for type 2 diabetes
30 June 2021 - Report will be subject of New England CEPAC meeting in January 2022; draft scoping document open ...
Posted by Michael Wonder on 30 Jun 2021
In revised evidence report, ICER confirms judgment that evidence is insufficient to demonstrate net health benefit of aducanumab for patients with Alzheimer’s disease
30 June 2021 - Accepting the uncertainty associated with the positive estimate obtained from pooled data from both pivotal trials, ...
Posted by Michael Wonder on 21 Jun 2021
Are drugs priced in accordance with value? A comparison of value based and net prices using Institute for Clinical and Economic Review reports
19 June 2021 - The Institute for Clinical and Economic Review is an independent organisation that reviews drugs and devices with ...
Posted by Michael Wonder on 07 Jun 2021
ICER issues statement on the FDA’s approval of aducanumab for Alzheimer’s disease
7 June 2021 - The ICER believes that the FDA, in approving aducanumab (Aduhelm, Biogen) for the treatment of Alzheimer’s ...